|

Balstilimab Clinical Trials

20 actively recruiting trials across 13 locations

▲ +3 trials since August 2026

Also known as: AGEN 2034, AGEN-2034, AGEN2034, AGEN2034, anti-PD-1 antibody, BAL +3 more

Pipeline

Early 1: 1Phase 1: 3Phase 2: 12Phase 3: 1Phase 1/2: 2Phase 2/3: 1

Top Sponsors

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2
  • National Cancer Institute (NCI)2
  • Memorial Sloan Kettering Cancer Center2
  • City of Hope Medical Center2
  • Weill Medical College of Cornell University1

Indications

  • Cancer20
  • Colorectal Cancer4
  • Liver Disease2
  • Microsatellite Stable Rectal Carcinoma2
  • Metastatic Pancreatic Cancer2

Other4 trials

Baltimore, Maryland2 trials

Boston, Massachusetts2 trials

Basking Ridge, New Jersey2 trials

Phase 2
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Goodyear, Arizona1 trial

Duarte, California1 trial

Fullerton, California1 trial

Orange, California1 trial

New Haven, Connecticut1 trial

Miami, Florida1 trial

Chicago, Illinois1 trial

New Orleans, Louisiana1 trial

New York, New York1 trial

Phase 2

Houston, Texas1 trial

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.